Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.
作者信息
Zingone Fabiana, Savarino Edoardo Vincenzo
机构信息
Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35121 Padua, Italy.
Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35121 Padua, Italy.
出版信息
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):525. doi: 10.1016/S2468-1253(20)30085-6. Epub 2020 Mar 25.
Abstract
摘要
相似文献
1
Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.在新冠疫情期间，对炎症性肠病患者使用生物制剂前进行病毒筛查。
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):525. doi: 10.1016/S2468-1253(20)30085-6. Epub 2020 Mar 25.
2
Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease.生物疗法可能降低炎症性肠病患者感染 COVID-19 的风险。
Inflamm Bowel Dis. 2020 Sep 18;26(10):e107-e109. doi: 10.1093/ibd/izaa242.
3
Reply: "Biologics for psoriasis during COVID-19 outbreak".回复：“新冠疫情期间用于银屑病的生物制剂”
J Am Acad Dermatol. 2020 Jun;82(6):e217-e218. doi: 10.1016/j.jaad.2020.04.004. Epub 2020 Apr 10.
4
Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak.雾化吸入在炎症性肠病管理中的应用：新冠疫情期间炎症性肠病发作的一个罕见病例
Inflamm Bowel Dis. 2020 Sep 18;26(10):e128-e129. doi: 10.1093/ibd/izaa184.
5
IBD in the Times of COVID-19.新冠疫情时代的炎症性肠病
Inflamm Bowel Dis. 2020 Jul 17;26(8):e92. doi: 10.1093/ibd/izaa132.
6
Clinical and Psychological Issues in Children with Inflammatory Bowel Disease During COVID-19 Pandemic.新冠疫情期间炎症性肠病患儿的临床与心理问题
Inflamm Bowel Dis. 2020 Aug 20;26(9):e95-e96. doi: 10.1093/ibd/izaa136.
7
Biological treatment during COVID-19 outbreak.新冠疫情期间的生物治疗。
J Dermatolog Treat. 2020 Jun;31(4):324. doi: 10.1080/09546634.2020.1749548. Epub 2020 Apr 13.
8
Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.初步数据表明，皮肤科使用的生物制剂与新冠肺炎不良结局无关。
J Cutan Med Surg. 2020 Jul/Aug;24(4):420-421. doi: 10.1177/1203475420929250. Epub 2020 May 25.
9
Reply to the Letter to the Editor: The Incidence and Outcomes of COVID-19 in Patients With IBD: A Rapid Review and Meta-Analysis.致编辑的信的回复：炎症性肠病患者中新冠病毒病的发病率和结局：快速综述与荟萃分析
Inflamm Bowel Dis. 2020 Sep 18;26(10):e127. doi: 10.1093/ibd/izaa172.
10
COVID-19 vaccinations in patients with inflammatory bowel disease.炎症性肠病患者的新冠病毒疫苗接种
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):965-966. doi: 10.1016/S2468-1253(20)30295-8. Epub 2020 Sep 21.
引用本文的文献
1
Inflammatory bowel diseases during the COVID-19 pandemic.新冠疫情期间的炎症性肠病
Prz Gastroenterol. 2024;19(3):231-235. doi: 10.5114/pg.2024.143143. Epub 2024 Sep 18.
2
Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements.韩国肠道疾病研究协会关于2019冠状病毒病大流行期间成人炎症性肠病临床实践的指南：专家共识声明
Intest Res. 2022 Oct;20(4):431-444. doi: 10.5217/ir.2021.00111. Epub 2022 Jan 5.
3
Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future.COVID-19 对炎症性肠病实践的影响及未来展望。
World J Gastroenterol. 2021 Sep 7;27(33):5520-5535. doi: 10.3748/wjg.v27.i33.5520.
4
Viral infections in inflammatory bowel disease: Tips and tricks for correct management.炎症性肠病中的病毒感染：正确管理的技巧与窍门。
World J Gastroenterol. 2021 Jul 21;27(27):4276-4297. doi: 10.3748/wjg.v27.i27.4276.
5
COVID-19 illness and autoimmune diseases: recent insights.COVID-19 疾病与自身免疫性疾病：最新见解。
Inflamm Res. 2021 Apr;70(4):407-428. doi: 10.1007/s00011-021-01446-1. Epub 2021 Feb 28.
6
COVID-19: Implications for People with Chagas Disease.新型冠状病毒肺炎：对恰加斯病患者的影响。
Glob Heart. 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
7
Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study.远程医疗时代炎症性肠病患者对新冠疫情的认知：横断面问卷调查研究
J Med Internet Res. 2020 Nov 2;22(11):e19574. doi: 10.2196/19574.
8
Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?炎症性肠病患者在开始生物治疗前是否应进行新型冠状病毒肺炎（COVID-19）活动性检测？
Gastroenterology. 2021 Jun;160(7):2626-2627. doi: 10.1053/j.gastro.2020.08.049. Epub 2020 Aug 30.
9
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic.英国炎症性肠病服务在新冠疫情期间的组织变革与挑战
Frontline Gastroenterol. 2020 Jun 16;11(5):343-350. doi: 10.1136/flgastro-2020-101520. eCollection 2020.
10
Bioinformatic Analysis of Correlation between Immune Infiltration and COVID-19 in Cancer Patients.生物信息学分析癌症患者中免疫浸润与 COVID-19 的相关性。
Int J Biol Sci. 2020 Jul 6;16(13):2464-2476. doi: 10.7150/ijbs.48639. eCollection 2020.
本文引用的文献
1
Implications of COVID-19 for patients with pre-existing digestive diseases.2019冠状病毒病对患有既往消化系统疾病患者的影响。
Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427. doi: 10.1016/S2468-1253(20)30076-5. Epub 2020 Mar 11.
2
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.中重度活动型溃疡性结肠炎患者的一线和二线药物治疗：一项更新的网络荟萃分析。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13.
3
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.英国胃肠病学会成人炎症性肠病管理共识指南。
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
4
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.克罗恩病活动度及同时使用的免疫抑制剂影响接受阿达木单抗治疗患者发生严重感染和机会性感染的风险。
Am J Gastroenterol. 2016 Dec;111(12):1806-1815. doi: 10.1038/ajg.2016.433. Epub 2016 Sep 27.
5
Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.抗肿瘤坏死因子-α治疗炎症性肠病中的机会性感染：随机对照试验的荟萃分析。
Am J Gastroenterol. 2013 Aug;108(8):1268-76. doi: 10.1038/ajg.2013.138. Epub 2013 May 7.
6
A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease.炎症性肠病患者机会性感染的发生率及危险因素的前瞻性分析。
J Gastroenterol. 2013 May;48(5):595-600. doi: 10.1007/s00535-012-0686-9. Epub 2012 Oct 5.
7
Risk factors for opportunistic infections in patients with inflammatory bowel disease.炎症性肠病患者机会性感染的危险因素。
Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11.
Zotero 插件